SCHEMBL25877825

SCHEMBL25877825

COc1cc(C=O)c(I)c(OCc2ccccc2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.47
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
BCHE P06276 2/20 0.42
TUBB1 Q9H4B7 1/20 0.42
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCNB1 P14635 1/20 0.42
CCND1 P24385 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42
MAPK1 P28482 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
APP P05067 1/20 0.40
HTR1A P08908 2/20 0.40
ADRA1D P25100 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24140819 0.90 ERN1 (0.49) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877366 0.88 ERN1 (0.50) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877360 0.85 MAPT (0.52) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877356 0.85 ERN1 (0.49) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877383 0.84 ERN1 (0.46) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL13116213 0.83 ERN1 (0.43) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL24140500 0.83 ERN1 (0.50) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877824 0.81 ERN1 (0.47) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877395 0.81 ERN1 (0.47) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL25877750 0.80 ERN1 (0.49) ERN1MAPTL3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B ERN1 258/4885MAPT 3694/4885L3MBTL1 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.